Drug intelligence / Profile preview

Colpermin

Development stage
Unknown
Lead developer
Tillotts Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Colpermin is an enteric-coated capsule containing 187 mg of peppermint oil (Mentha x piperita), used for the symptomatic treatment of irritable bowel syndrome (IBS). The enteric coating is designed to delay the release of the active ingredient until it reaches the small intestine, thereby providing local action on the bowel wall while reducing the risk of upper gastrointestinal side effects like heartburn. Its primary mechanism of action is the inhibition of L-type voltage-gated calcium channels in intestinal smooth muscle cells, which leads to muscle relaxation and an antispasmodic effect. This helps alleviate common IBS symptoms such as abdominal pain, bloating, and flatulence. In clinical research conducted by the Shiraz University of Medical Sciences, Colpermin has served as a gold-standard active comparator in Phase 3 trials evaluating the efficacy of other botanical extracts, such as anise oil, for gastrointestinal disorders.

Brand names
Colpermin
Other names
peppermint oilMentha x piperita oilenteric-coated peppermint oil
02

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on Colpermin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colpermin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call